Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.
Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma
James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.
Enfortumab Vedotin Combo Earns Japanese Approval for Urothelial Carcinoma
Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.
Developers Resubmit NDA for Camrelizumab Combo in Unresectable Liver Cancer
Updated findings from the CARES-310 trial support the resubmitted application for camrelizumab/rivoceranib in unresectable hepatocellular carcinoma.
Fruquintinib Approved in Japan for Unresectable Advanced or Recurrent CRC
The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care
Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.
Finding Mentors and Forging Connections in the Brain Cancer Field
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Zolbetuximab Earns European Approval in Advanced CLDN18.2+ Gastric Cancer
Data from the GLOW and SPOTLIGHT trials support the European Commission’s approval of zolbetuximab for patients with CLDN18.2-positive gastric cancer.
Anthracyclines Improve Survival at the Expense of Home Time in AML
A SEER-Medicare database analysis of patients with AML illustrates a trade-off between survival outcomes and time spent in hospitals.
Dato-DXd Misses OS End Point in TROPION-Breast01 Trial of HR+ Breast Cancer
Datopotamab deruxtecan previously showed statistically significant improvement in progression-free survival in patients with HR+, HER2-low, or HER2-negative breast cancer.
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.
Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial
Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
Ovarian Function Suppression May Benefit Select Breast Cancer Populations
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.
Expediting Clinical Trial Processes to Advance Brain Cancer Research
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Exploring GPRC5D as an Important Target for Multiple Myeloma
Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.
FDA Approves Isatuximab/VRd in Newly Diagnosed Multiple Myeloma
Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.
2024 Statistics May Impact Next Decade of Cancer Treatment
Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.
Narmafotinib Earns FDA Fast Track Designation in Advanced Pancreatic Cancer
Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.
Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach
Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.
Amivantamab Plus Chemo Approved by FDA in EGFR-Mutated NSCLC
Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.
“Impactful” Data Presentations Raise Hope in the Breast Cancer Field
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Improving Day-to-Day Brain Cancer Care Via Multidisciplinary Collaboration
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Pelareorep Combo Yields Survival Benefit in HR+/HER2– Breast Cancer
Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.
Frontline Combination Therapy Intensification May Improve Survival in NSCLC
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC
Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.
Belantamab Mafodotin Combo Regimens Accepted for Review in Japan in R/R MM
A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.
Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL
Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.
